177 related articles for article (PubMed ID: 34004331)
21. Zika Virus: A New Therapeutic Candidate for Glioblastoma Treatment.
Francipane MG; Douradinha B; Chinnici CM; Russelli G; Conaldi PG; Iannolo G
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681654
[TBL] [Abstract][Full Text] [Related]
22. Standard therapy or additionally radioactive iodine (131I) therapy; which will stop the recurrence of glioblastoma multiforme (GBM)?
Czarnywojtek A; Gut P; Dyrka K; Sowiński J; Sawicka-Gutaj N; Katulska K; Stajgis P; Wykrętowicz M; Moskal J; Kościński J; Pietrończyk K; Graczyk P; Krawczyński MR; Florek E; Szczepanek-Parulska E; Ruchała M; Ferlito A
Endokrynol Pol; 2024; 75(2):130-139. PubMed ID: 38646982
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic immunoactivation associates with survival in a glioblastoma clinical trial.
Ling AL; Chiocca EA
Neuro Oncol; 2024 Feb; 26(2):209-210. PubMed ID: 37941468
[No Abstract] [Full Text] [Related]
24. Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma.
Ageenko A; Vasileva N; Richter V; Kuligina E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396720
[TBL] [Abstract][Full Text] [Related]
25. Virus-Based Immunotherapy of Glioblastoma.
Martikainen M; Essand M
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30764570
[TBL] [Abstract][Full Text] [Related]
26. The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment.
Nguyen HM; Saha D
Oncolytic Virother; 2021; 10():1-27. PubMed ID: 33659221
[TBL] [Abstract][Full Text] [Related]
27. Breaking Barriers: A Future Perspective on Glioblastoma Therapy with mRNA-Based Immunotherapies and Oncolytic Viruses.
Guterres A; Filho PNS; Moura-Neto V
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250874
[TBL] [Abstract][Full Text] [Related]
28. [Advances in oncolytic virotherapy for glioma].
Zhu GL; Wu S; Wu JS
Zhonghua Wai Ke Za Zhi; 2023 Dec; 62(1):78-83. PubMed ID: 38044611
[TBL] [Abstract][Full Text] [Related]
29. Differential Susceptibility of Ex Vivo Primary Glioblastoma Tumors to Oncolytic Effect of Modified Zika Virus.
Garcia G; Chakravarty N; Paiola S; Urena E; Gyani P; Tse C; French SW; Danielpour M; Breunig JJ; Nathanson DA; Arumugaswami V
Cells; 2023 Sep; 12(19):. PubMed ID: 37830597
[TBL] [Abstract][Full Text] [Related]
30. Glioma virus therapies between bench and bedside.
Kaufmann JK; Chiocca EA
Neuro Oncol; 2014 Mar; 16(3):334-51. PubMed ID: 24470549
[TBL] [Abstract][Full Text] [Related]
31. Navigating the Immune Challenge in Glioblastoma: Exploring Immunotherapeutic Avenues for Overcoming Immune Suppression.
Jain P; Vashist S; Panjiyar BK
Cureus; 2023 Sep; 15(9):e46089. PubMed ID: 37900496
[TBL] [Abstract][Full Text] [Related]
32. Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients.
Van Gool SW; Van de Vliet P; Kampers LFC; Kosmal J; Sprenger T; Reich E; Schirrmacher V; Stuecker W
Methods Cell Biol; 2024; 183():51-113. PubMed ID: 38548421
[TBL] [Abstract][Full Text] [Related]
33. oHSV-P10 reduces glioma stem cell enrichment after oncolytic HSV therapy.
Sahu U; Mullarkey MP; Pei G; Zhao Z; Hong B; Kaur B
Mol Ther Oncolytics; 2023 Jun; 29():30-41. PubMed ID: 37114074
[TBL] [Abstract][Full Text] [Related]
34. HIV-Encoded Gene Therapy as Anti-cancer Therapeutics: A Narrative Review.
Balakrishnan P; Sathish S; Saravanan S
Cureus; 2024 Feb; 16(2):e53431. PubMed ID: 38435173
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene.
Chiocca EA; Nakashima H; Kasai K; Fernandez SA; Oglesbee M
Mol Ther Methods Clin Dev; 2020 Jun; 17():871-893. PubMed ID: 32373649
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic Effect of Zika Virus in Neuroendocrine Pancreatic Tumors: New Perspectives for Therapeutic Approaches.
Cocco MM; Carcione C; Miceli V; Tinnirello R; Chinnici CM; Carbone C; Zito G; Conaldi PG; Iannolo G
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139100
[TBL] [Abstract][Full Text] [Related]
37. An autologous ex vivo model for exploring patient-specific responses to viro-immunotherapy in glioblastoma.
Stavrakaki E; van den Bossche WBL; Vogelezang LB; Teodosio C; Mustafa DM; van Dongen JJM; Dirven CMF; Balvers RK; Lamfers ML
Cell Rep Methods; 2024 Mar; 4(3):100716. PubMed ID: 38430913
[TBL] [Abstract][Full Text] [Related]
38. A NEW HYPOTHESIS IN THE TREATMENT OF RECURRENT GLIOBLASTOMA MULTIFORME (GBM). PART 1: INTRODUCTION.
Czarnywojtek A; Gut P; Borowska M; Dyrka K; Ruchała M; Ferlito A
Pol Merkur Lekarski; 2023; 51(4):430-432. PubMed ID: 37756465
[TBL] [Abstract][Full Text] [Related]
39. Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma.
Webb MJ; Sener U; Vile RG
Pharmaceuticals (Basel); 2023 May; 16(6):. PubMed ID: 37375742
[TBL] [Abstract][Full Text] [Related]
40. Intranasal Delivery of Oncolytic Adenovirus XVir-N-31 via Optimized Shuttle Cells Significantly Extends Survival of Glioblastoma-Bearing Mice.
El-Ayoubi A; Klawitter M; Rüttinger J; Wellhäusser G; Holm PS; Danielyan L; Naumann U
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
